Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  AJP - Renal Physiology

• Publication date

  2015-08-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1152/ajprenal.00689.2014PMID 26041448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of sodium‐linked glucose reabsorption normalizes diabetes‐induced glomerular hyperfiltration in conscious adenosine A1‐receptor deficient mice

  2014cited by this paper
• Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans

  2014cited by this paper
• L-Citrulline, But Not L-Arginine, Prevents Diabetes Mellitus–Induced Glomerular Hyperfiltration and Proteinuria in Rat

  2014cited by this paper
• SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

  2014cited by this paper
• Cardinal Role of the Intrarenal Renin-Angiotensin System in the Pathogenesis of Diabetic Nephropathy

  2013cited by this paper
• Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension

  2013cited by this paper
• LX4211 Increases Serum Glucagon-Like Peptide 1 and Peptide YY Levels by Reducing Sodium/Glucose Cotransporter 1 (SGLT1)–Mediated Absorption of Intestinal Glucose

  2013cited by this paper
• Diabetic nephropathy: diagnosis, prevention and treatment

  2013cited by this paper
• Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.

  2013cited by this paper
• GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

  2013cited by this paper
• Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats

  2012cited by this paper
• Mechanisms of Glomerular Albumin Filtration and Tubular Reabsorption

  2012cited by this paper
• Acute Knockdown of Uncoupling Protein-2 Increases Uncoupling via the Adenine Nucleotide Transporter and Decreases Oxidative Stress in Diabetic Kidneys

  2012cited by this paper
• SGLT2 mediates glucose reabsorption in the early proximal tubule

  2010cited by this paper
• Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats.

  2010cited by this paper
• Tubular reabsorption and diabetes‐induced glomerular hyperfiltration

  2010cited by this paper
• Adenosine A1 Receptors Determine Glomerular Hyperfiltration and the Salt Paradox in Early Streptozotocin Diabetes Mellitus

  2009cited by this paper
• Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis

  2009cited by this paper
• Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody.

  2008cited by this paper
• Diabetes-induced up-regulation of uncoupling protein-2 results in increased mitochondrial uncoupling in kidney proximal tubular cells.

  2008cited by this paper
• Phlorizin Prevents Glomerular Hyperfiltration but not Hypertrophy in Diabetic Rats

  2008cited by this paper
• Diabetes‐induced hyperfiltration in adenosine A1‐receptor deficient mice lacking the tubuloglomerular feedback mechanism

  2007cited by this paper
• Renal albumin absorption in physiology and pathology.

  2006cited by this paper
• Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

  2005cited by this paper
• Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension

  2003cited by this paper
• Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats.

  2001cited by this paper
• Improved diabetic syndrome in C57BL/KsJ‐db/db mice by oral administration of the Na+‐glucose cotransporter inhibitor T‐1095

  2001cited by this paper
• Changes in Sodium or Glucose Filtration Rate Modulate Expression of Glucose Transporters in Renal Proximal Tubular Cells of Rat

  2001cited by this paper
• Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption.

  1999cited by this paper
• Role of nitric oxide in the control of renal oxygen consumption and the regulation of chemical work in the kidney.

  1998cited by this paper
• Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus.

  1995cited by this paper
• Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats.

  1994cited by this paper
• Increased Renal Metabolism in Diabetes: Mechanism and Functional Implications

  1994cited by this paper
• Glomerular filtration and tubular reabsorption of albumin in preproteinuric and proteinuric diabetic rats.

  1993cited by this paper
• Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat.

  1992cited by this paper
• Increased glomerular filtration rate as a predictor of diabetic nephropathy--an 8-year prospective study.

  1992cited by this paper
• Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus.

  1991cited by this paper
• Renal Metabolism: Integrated Responses

  1991cited by this paper
• Role of nitric oxide in renal medullary oxygenation. Studies in isolated and intact rat kidneys.

  1991cited by this paper
• Factors affecting the urinary excretion of albumin in insulin-dependent diabetes.

  1987cited by this paper
• Renal function in streptozotocin-diabetic rats

  1981cited by this paper
• Brown-adipose-tissue mitochondria: photoaffinity labelling of the regulatory site of energy dissipation.

  1978cited by this paper

• Amino acid infusion and SGLT2 inhibitors for kidney protection: Plausible adverse impact of tubular transport load on renal tissue oxygenation.

  2026cites this paper
• The impact of short-term administration of dapagliflozin on contrast-induced acute kidney injury in patients with type 2 diabetes and renal insufficiency undergoing percutaneous coronary intervention

  2025cites this paper
• Progress in the Study of the Effect of SGLT2 Inhibitors on Glomerular Filtration Rate and Its Mechanism

  2025cites this paper
• Effect of sodium-glucose co-transporter 2 inhibitor on contrast-induced acute kidney injury and prognosis in type 2 diabetes patients undergoing percutaneous coronary intervention

  2025cites this paper
• Sustained eGFR improvement after dapagliflozin in a patient with antiretroviral therapy-related chronic kidney disease

  2025cites this paper
• SGL-TX-MR—study protocol acute effects of SGLT2 inhibitor on kidney allograft oxygen tension, a randomized, double-blind, placebo controlled crossover trial

  2025cites this paper
• Risk of acute renal failure associated with combined use of SGLT2 inhibitors and potentially nephrotoxic drugs: an epidemiological surveillance study based on the FDA adverse event reporting system (FAERS).

  2025cites this paper
• Ertugliflozin mitigates renal ischemia-reperfusion injury through the downregulation of HIF-1α expression.

  2025cites this paper
• Sodium-glucose co-transporter inhibitors for APOL1 kidney disease: A call for studies

  2025cites this paper
• SGLT2 Inhibitors and the Risk of Contrast-Associated Nephropathy Following Angiographic Intervention: Contradictory Concepts and Clinical Outcomes

  2024cites this paper
• Heterogeneous afferent arteriolopathy: a key concept for understanding blood pressure–dependent renal damage

  2024cites this paper
• SGLT2-Independent Effects of Canagliflozin on NHE3 and Mitochondrial Complex I Activity Inhibit Proximal Tubule Fluid Transport and Albumin Uptake

  2024cites this paper
• SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?

  2024cites this paper
• Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review.

  2024cites this paper
• SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback

  2024cites this paper
• Safety assessment of dapagliflozin: Real-world adverse event analysis based on the FAERS database from 2012 to 2023

  2024cites this paper
• Oxygen sensing in the kidney.

  2024cites this paper
• Tofogliflozin attenuates renal lipid deposition and inflammation via PPARα upregulation mediated by miR-21a impairment in diet-induced steatohepatitic mice

  2024cites this paper
• Insightful Perspectives on Sodium-glucose Co-transporter 2 Inhibitors: Navigating Safety Updates and Beyond.

  2024cites this paper
• Phlorizin, an Important Glucoside: Research Progress on Its Biological Activity and Mechanism

  2024cites this paper
• Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin—a post-hoc analysis of the UTOPIA study

  2024cites this paper
• Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities

  2024cites this paper
• Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes

  2024cites this paper
• Inhibition of sodium‐glucose cotransporter‐2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model

  2024cites this paper
• Tip 2 Diyabetli Hastalarda SGLT2 İnhibitörlerinin Hematolojik Parametreler Üzerindeki Etkileri: Retrospektif Bir Çalışma

  2024cites this paper
• Renal handling of albumin in rats with early stage diabetes: A theoretical analysis

  2024cites this paper
• The importance of proinflammatory failed-repair tubular epithelia as a predictor of diabetic kidney disease progression

  2024cites this paper
• Effects of sodium-glucose transporter-2 inhibition on systemic hemodynamics, renal function, and intra-renal oxygenation in sepsis-associated acute kidney injury

  2024cites this paper
• SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA

  2023cites this paper
• Did you know how SGLT2 inhibitors protect the kidney?

  2023cites this paper
• Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors

  2023cites this paper
• Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors

  2023cites this paper
• Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart

  2023cites this paper
• Novel Perspectives Regarding the Physiologic Mechanisms by which Gliflozins Induce Reticulocytosis and Erythrocytosis.

  2023cites this paper
• Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial

  2023cites this paper
• Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease

  2023cites this paper
• Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

  2023influential citation
• Gliflozins, Erythropoietin, and Erythrocytosis: Is It Renal Normoxia- or Hypoxia-Driven?

  2023cites this paper
• Acute kidney injury in diabetes mellitus: Epidemiology, diagnostic, and therapeutic concepts

  2023cites this paper
• Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study

  2023cites this paper
• SGLT2 inhibitors, intrarenal hypoxia and the diabetic kidney: insights into pathophysiological concepts and current evidence

  2023cites this paper
• Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease

  2023cites this paper
• Oxidative Stress Induced by Lipotoxicity and Renal Hypoxia in Diabetic Kidney Disease and Possible Therapeutic Interventions: Targeting the Lipid Metabolism and Hypoxia

  2023cites this paper
• Sodium–Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review

  2023cites this paper
• Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct

  2023cites this paper
• Hypoxia and renal fibrosis.

  2023cites this paper
• Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus

  2023cites this paper
• Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease

  2023cites this paper
• Reducing Oxygen Demand to Alleviate Acute Kidney Injury.

  2023cites this paper
• Dapagliflozin for the treatment of chronic kidney disease

  2022cites this paper
• SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis

  2022cites this paper
• Cardiorenal protections of SGLT2 inhibitors in the treatment of type 2 diabetes.

  2022cites this paper
• Contrast-Induced Acute Kidney Injury in Diabetic Patients and SGLT-2 Inhibitors: A Preventive Opportunity or Promoting Element?

  2022cites this paper
• Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors

  2022cites this paper
• Sodium-glucose co-transporter 2 inhibitors and erythrocytosis: a review

  2022cites this paper
• The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1.

  2022cites this paper
• Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology.

  2022cites this paper
• Hypoxia-inducible factor signaling in vascular calcification in chronic kidney disease patients

  2022cites this paper
• Evaluation Of Anti-Biofilm Activity Of Bacterial Amylase Against Human Pathogens

  2022cites this paper
• Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level

  2022cites this paper
• An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors

  2022cites this paper
• SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice

  2022cites this paper
• Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project

  2022cites this paper
• Renoprotective Effects of SGLT2 Inhibitors.

  2022cites this paper
• Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus.

  2022cites this paper
• Diabetic Proteinuria Revisited: Updated Physiologic Perspectives

  2022cites this paper
• Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin

  2022cites this paper
• Sodium‐glucose co‐transporter 2 inhibitors and hematopoiesis

  2022cites this paper
• Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?

  2022cites this paper
• SGLT-2 inhibitors and nephroprotection in patients with diabetic and non-diabetic chronic kidney disease.

  2022cites this paper
• Gliflozins in the Management of Cardiovascular Disease.

  2022cites this paper
• Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study

  2022cites this paper
• From your kidneys to your eyes: lessons from computational kidney models

  2022cites this paper
• Role of abnormal energy metabolism in the progression of chronic kidney disease and drug intervention

  2022influential citation
• Youth versus adult-onset type 2 diabetic kidney disease: Insights into currently known structural differences and the potential underlying mechanisms.

  2022cites this paper
• Sodium‐glucose cotransporter‐2 inhibitors and non‐steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin‐angiotensin system blockade

  2021cites this paper
• The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

  2021cites this paper
• Impact of sodium glucose linked cotransporter‐2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus

  2021influential citation
• Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors

  2021cites this paper
• The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.

  2021cites this paper
• Beneficial effects on kidney during treatment with sodium-glucose cotransporter 2 inhibitors: proposed role of ketone utilization

  2021cites this paper
• Dapagli ozin Attenuates Diabetic Cardiomyopathy Through Erythropoietin Up-Regulation of AKT/JAK/MAPK Pathways in Streptozotocin- Induced Diabetic Rats

  2021cites this paper
• Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.

  2021cites this paper
• SGLT-2 inhibitors in heart failure: An updated systematic review and meta-analysis of 13 randomized clinical trials including 14618 patients with heart failure.

  2021cites this paper
• Renal Tubular Handling of Glucose and Fructose in Health and Disease.

  2021cites this paper
• Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis.

  2021cites this paper
• Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system

  2021cites this paper
• Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review

  2021cites this paper
• Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: a comprehensive review with a special reference to RAAS blockers.

  2021cites this paper
• SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.

  2021cites this paper
• Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice

  2021cites this paper
• Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease

  2021cites this paper
• Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease

  2021cites this paper
• Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial

  2021cites this paper
• Energy Requirements for Older Patients with Type 2 Diabetes: A Narrative Review of the Current Findings and Future Tasks

  2021cites this paper
• Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats.

  2021cites this paper
• A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors.

  2021cites this paper
• Protective effect of dapagliflozin on colistin-induced renal toxicity

  2021cites this paper
• A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.

  2021cites this paper
• Mitochondria in Diabetic Kidney Disease

  2021influential citation